Viking Therapeutics Advances Phase III Trials for VK2735 in Obesity
Viking Therapeutics (NASDAQ:VKTX) announced that its Phase III VANQUISH program for injectable VK2735 is progressing as planned. The company expects to begin oral dosing of the drug candidate by the fourth quarter, with a target duration of up to 78 weeks. According to CEO Brian Lian during Q2 2026 earnings call insights, both VANQUISH-1 and VANQUISH-2 trials—targeted at obesity and type 2 diabetes—are fully enrolled. The company emphasized that the program is on track for advancement as scheduled.
Tickers: $VKTX
Topics: biotech obesity treatment pharmaceuticals Phase III trials